Compare · head to head
Lexicon Pharmaceuticals vs MannKind
Lexicon Pharmaceuticals ranks higher overall — 360 rank 28 vs 24.
MannKind leads on Quality (62 vs 43). Lexicon Pharmaceuticals leads on Growth (45 vs 37), Safety (32 vs 15) and Sentiment (57 vs 50).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals | Biotechnology |
| Size | Small | Medium |
| ISIN | US5288723027 | US56400P7069 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 28 | 24 |
| Value | NR | 58 |
| Quality | 43 | 62 |
| Growth | 45 | 37 |
| Safety | 32 | 15 |
| Sentiment | 57 | 50 |
| Quality details | ||
| Profitability | 35 | 77 |
| Cash Truth | NR | 47 |
Lexicon Pharmaceuticals vs Kura OncologyLexicon Pharmaceuticals vs Kestra Medical TechnologiesLexicon Pharmaceuticals vs Xeris PharmaceuticalsAdd a third stock →
Full analyses: Lexicon Pharmaceuticals · MannKind
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100